Page last updated: 2024-08-21

2-aminopurine and Cytomegaloviral Retinitis

2-aminopurine has been researched along with Cytomegaloviral Retinitis in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (33.33)18.2507
2000's1 (33.33)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cunningham, ET; Fu, A; Johnson, RN; Jumper, JM; Lujan, BJ; McDonald, HR; Wong, RW1
Emerson, GG; Flaxel, CJ; Rosenbaum, JT; Smith, JR; Wilson, DJ1
Highleyman, L1

Reviews

1 review(s) available for 2-aminopurine and Cytomegaloviral Retinitis

ArticleYear
Emerging concepts in the management of acute retinal necrosis.
    The British journal of ophthalmology, 2013, Volume: 97, Issue:5

    Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Cytomegalovirus Retinitis; Eye Infections, Viral; Famciclovir; Fluorescein Angiography; Ganciclovir; Herpes Simplex; Humans; Laser Coagulation; Retinal Necrosis Syndrome, Acute; Valacyclovir; Valganciclovir; Valine

2013

Other Studies

2 other study(ies) available for 2-aminopurine and Cytomegaloviral Retinitis

ArticleYear
Primary treatment of acute retinal necrosis with oral antiviral therapy.
    Ophthalmology, 2006, Volume: 113, Issue:12

    Topics: 2-Aminopurine; Acyclovir; Administration, Oral; Adult; Aged; Antiviral Agents; Cytomegalovirus Retinitis; Drug Therapy, Combination; Famciclovir; Female; Glucocorticoids; Herpes Simplex; Herpes Zoster Ophthalmicus; Herpesvirus 1, Human; Herpesvirus 2, Human; Herpesvirus 3, Human; Humans; Male; Middle Aged; Retinal Necrosis Syndrome, Acute; Retrospective Studies; Valacyclovir; Valine; Visual Acuity; Vitreous Body

2006
FDA approves fomivirsen, famciclovir, and Thalidomide. Food and Drug Administration.
    BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation, 1998

    Topics: 2-Aminopurine; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Drug Approval; Famciclovir; Herpes Simplex; Herpes Zoster; HIV Wasting Syndrome; Humans; Leprostatic Agents; Leprosy; Thalidomide; Thionucleotides; United States; United States Food and Drug Administration

1998